All articles by Hemanth Kumar
Hemanth Kumar
Top ten pharma companies in 2020
The global pharmaceutical industry is expected to witness positive growth as the top pharma companies are at forefront of the fight against COVID-19.
Filgotinib shows improvements in rheumatoid arthritis trial
A Phase III clinical trial led by a Stanford University School of Medicine investigator has demonstrated that Gilead Sciences’ filgotinib led to substantial improvements in rheumatoid arthritis patients who did not respond to existing therapies.
Tiziana reveals positive results for Milciclib in liver cancer trial
Tiziana Life Sciences has reported that Milciclib was well-tolerated in a Phase IIa clinical trial involving participants with advanced hepatocellular carcinoma (HCC).
Intec’s late-stage Parkinson’s study fails to meet endpoints
Intec Pharma has reported top-line results from the Phase III ACCORDANCE clinical trial of its Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) to treat the symptoms of advanced Parkinson’s disease (PD).
Sandoz starts enrolment in biosimilar denosumab trial
Novartis subsidiary Sandoz has commenced patient enrolment in the Phase I/III ROSALIA clinical trial of its proposed biosimilar denosumab to treat osteoporosis.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Marker reports positive data from pancreatic cancer trial
Marker Therapeutics has reported positive interim results from an ongoing TACTOPS clinical trial evaluating Multi-Antigen Targeted (MultiTAA) T-cell therapy for the treatment of pancreatic adenocarcinoma.
Takeda’s study of subcutaneous vedolizumab meets primary goal
Takeda Pharmaceutical has reported that the VISIBLE 2 clinical trial of a subcutaneous (SC) formulation of vedolizumab met its primary endpoint in adults with moderately to severely active Crohn’s disease (CD).
Adaptimmune initiates first trial of new SPEAR T-cell asset
Adaptimmune Therapeutics has started the first clinical trial (SURPASS) of its next-generation SPEAR T-cell, ADP‑A2M4CD8, for the treatment of solid tumours.
BMS, Ono, and Bayer partner to trial combination therapy for mCRC
Bristol-Myers Squibb (BMS), Ono Pharmaceutical, and Bayer have signed a clinical collaboration agreement to trial a combination therapy for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC).